Dr. Ramon Llull tells his story of his involvement with the science of TRUE NanoFat Points of Discussion Dr. Lull’s history with Tulip NanoFatRecent studies and developmentsWhat’s next for NanoFat
Tulip Sponsors FDA Study for COVID-19 Patients
Just published in the Journal of Current Medical Research and Opinion
SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.
Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.
Tulip Medical is grateful to have the opportunity to sponsor this trial and provide surgical instrumentation for it.
Share thoughts, questions, and comments on this article.
Dr. Robert Alexander talks about his involvement with TRUE NanoFat Points of Discussion Dr. Alexander’s history with Tulip NanoFat How Tulip NanoFat differs from its competitors Beyond Cosmetic Purposes Examples
Points of Discussion Dr. Muaricio’s background Micronizing fat Tulip NanoFat versatility The benefits of NanoFat Future improvements The Interview Interviewer: We’re here with a board certified dermatologist and the founder